Insulet PODD Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Product | ||||||
| Drug Delivery | $3.3M+73.7% | $1.9M-73.2% | $7.1M-30.4% | $10.2M-31.5% | $14.9M+26.3% | |
| International | $242.9M+13.5% | $214.1M+5.9% | $202.1M+8.8% | $185.8M+22.0% | $152.3M+7.3% | |
| Total Omnipod products | $758.4M-3.0% | $781.8M+11.8% | $699.2M+9.4% | $639M+15.3% | $554M-5.4% | |
| U.S.Omnipod | $515.6M-9.2% | $567.8M+14.2% | $497.1M+9.7% | $453.2M+12.8% | $401.7M-9.5% | |
| Property, plant and equipment, net by Geography | ||||||
| Malaysia | $224.7M+2.1% | $220M+34.0% | $164.2M+2.1% | $160.9M+2.0% | $157.8M-0.8% | |
| Other | $136.4M+7.5% | $126.9M+447% | $23.2M+26.1% | $18.4M+36.3% | $13.5M+39.2% | |
| U.S. | $469.3M-0.7% | $472.5M+2.3% | $461.9M-0.9% | $465.9M-1.2% | $471.4M-0.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Insulet break its business down?
- Insulet (PODD) reports total revenue by product across 4 parts — Drug Delivery, International, Total Omnipod products and U.S.Omnipod. Each is extracted from the segment footnotes and tracked over time.
- Where does Insulet's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Insulet's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
